Amber Orman

Amber Orman

Auto-generated profile, based on publicly available information

Amber Orman

Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, Florida

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2014 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
AOAmber Orman
Amber Orman
TKTulay Koru-Sengul
Tulay Koru-Sengul
FMFeng Miao
Feng Miao
AMArnold Markoe
Arnold Markoe
JPJoseph E. Panoff
Joseph E. Panoff

1 June 2016 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
EBElizabeth L. Bossart
Elizabeth L. Bossart
RSRadka Stoyanova
Radka Stoyanova
KSKiri Sandler
Kiri Sandler
MSMatthew Studenski
Matthew Studenski
AOAmber Orman
Amber Orman
APAlan Pollack
Alan Pollack

1 June 2017 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Open access
PDF file
AOAmber G. Orman
Amber G. Orman
ZMZhenjun Ma
Zhenjun Ma
JZJun-Min Zhou
Jun-Min Zhou
DPDiane Portman
Diane Portman
HJHeather S. L. Jim
Heather S. L. Jim
MYMichael Yu
Michael Yu
There is increasing recognition of the importance of assessing patient-reported symptoms as part of clinical care. Recent randomized trials of clinic-based symptom monitoring have found that it is associated with reduced symptom severity, better quality of life, and reduced hospitalization and emergency room visits. Our clinic established use of a modified Edmonton Symptom Assessment Scale (ESAS) in August 2015. All patients presenting for radiation oncology (RO) services complete the form at each clinic visit. As these patients often experience multiple symptoms that affect quality of life and outcomes, recent symptom management literature focuses on identifying symptom clusters.

26 June 2025
Verified
Book Chapter
Closed access
PDF file
AOAmber Orman
Amber Orman
MRMeghana Reddy
Meghana Reddy
GKGautam Krishna Koipallil
Gautam Krishna Koipallil
Despite advancements in screening, diagnosis, and treatment, cancer remains the second leading cause of death in the US since 1938, surpassed only by heart disease. Lifestyle medicine (LM) is positioned to influence not only cancer incidence but also the quality of life for cancer survivors and their overall health outcomes, both cancer-specific and general. Guidelines applicable to both primary and tertiary prevention will be reviewed, emphasizing the importance of LM pillars to include maintaining a healthy body weight, following a plant-predominant nutrition plan, limiting red meat and avoiding processed meat, restricting sugar-sweetened drinks, engaging in sufficient physical activity, and avoiding alcohol consumption and tobacco use. The recommendation to engage in aerobic and resistance exercise with curative intent to mitigate side effects associated with cancer therapy will be discussed. Experiential approaches to care delivery will be presented to facilitate effective implementation. Case studies will be presented focusing on premenopausal and postmenopausal breast cancer. <!----> <!----> <!----> <!---->

1 October 2016 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
MGM. Green
M. Green
AAA.A. Ahmed
A.A. Ahmed
EHEmma Brey Holliday
Emma Brey Holliday
SYS.K. Yoo
S.K. Yoo
AOA. Orman
A. Orman
LWL.D. Wilson
L.D. Wilson

1 March 2015 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
NCNicholas Richard Cnossen
Nicholas Richard Cnossen
AOAmber Gail Orman
Amber Gail Orman
DKDeukwoo Kwon
Deukwoo Kwon
CRChad Ritch
Chad Ritch
MGMark Gonzalgo
Mark Gonzalgo
MAMatthew Abramowitz
Matthew Abramowitz
39 Background: Health-related quality of life (HRQoL) outcomes are important in treatment selection for prostate cancer. The Expanded Prostate Cancer Index Composite (EPIC) is a validated and widely-utilized HRQoL survey which accounts for newer radiotherapeutic, surgical, and hormonal treatment methods. We present a meta-analysis of patient reported HRQoL outcomes collected with EPIC and compare HRQoL trends with radiation therapy, surgery, or active surveillance as primary treatment. Methods: The PubMed database was systematically searched for all studies which presented data directly derived from the use of EPIC on patients with prostate cancer prior to 07/09/2014. All eligible studies were selected for either inclusion and analysis or exclusion based on pre-determined criteria. The data from included studies was compiled and a simulation-based estimation method using Approximate Bayesian Computation was performed to obtain missing standard deviation estimate. A longitudinal meta-analysis was conducted to estimate EPIC-profiles for each component using Bayesian p-spline method. Results: Over 4,000 studies were searched, 152 were deemed eligible, and 39 were included. The calculated mean summary score estimates are shown in the attached table. Conclusions: In the urinary domain, radical prostatectomy (RP) has lower acute scores than active surveillance (AS) or radiation therapy (RT) without long-term difference. In the bowel domain, RT has lower scores than AS or RP acutely and long-term. In the sexual domain, RT and RP have lower acute scores than AS. RP has lower scores than RT without long-term difference. In the hormonal domain, little difference was noted between modalities. [Table: see text]